Nevertheless, our meta-analysis provides the first pooled estimates of CDK4/6 inhibitor efficacy in elderly patients with advanced BC, and the final results were consistent in younger and older subjects in both PFS and OS analyses. Here, CDK4 is linked to breast cancer.